CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
Choong-kun Lee, Hong Jae Chon, Woo Sun Kwon, Hyo-Jeong Ban, Sang Cheol Kim, Hyunwook Kim, Hei-Cheul Jeung, Jimyung Chung, Sun Young Rha
Genomics Inform. 2022;20(3):e29  Published online September 30, 2022

Excel Download

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
Genomics & Informatics. 2022;20(3):e29   Crossref logo
Link1 Link2 Link3

Pricing transparency among several needs for patients with high‐risk breast cancer
Cancer. 2021;127(22):4122-4123   Crossref logo
Link1 Link2 Link3

Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population
BMJ. 2015;h4134   Crossref logo
Link1 Link2

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
Gastric Cancer. 2010;13(3):155-161   Crossref logo
Link1 Link2 Link3

Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study
Pediatric Blood & Cancer. 2012;60(2):242-247   Crossref logo
Link1 Link2 Link3

Predicting the Bleeding Risk for Patients on Anticoagulant Therapy Prior to Gastric Endoscopic Submucosal Dissection
Journal of Gastric Cancer. 2022;22(1):1   Crossref logo
Link1 Link2 Link3

Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer
Gastric Cancer. 2006;9(3):203-207   Crossref logo
Link1 Link2 Link3

A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)
Gastric Cancer. 2011;14(3):226-233   Crossref logo
Link1 Link2 Link3 Link4

Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
Medical Oncology. 2013;30(3):   Crossref logo
Link1 Link2 Link3

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
British Journal of Cancer. 2008;99(2):275-282   Crossref logo
Link1 Link2 Link3